Results of Operations and Financial Condition. On August 4, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended June 30, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Sect…

Results of Operations and Financial Condition. On June 17, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended March 31, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Sect…

Entry into a Material Definitive Agreement On May 7, 2026, Odyssey Therapeutics, Inc. (the “ Company ”) entered into a Share Purchase Agreement (the “ Purchase Agreement ”) with TPG LSI Rise Orazio II, L.P. (“ Purchaser ”), an affiliate of an existing stockholder of the Company, for the purchase of an aggregate of 1,388,889 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 (the “ Common Stock ”), at a per share price equal to the initial public offering price of $18.00 p…

The Shares have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), or applicable state securities laws, and were issued and sold pursuant to Section 4(a)(2) of the Securities Act. The Purchaser has represented that it is an “institutional accredited investor” within the meaning of Rule 501 of Regulation D under the Securities Act or a “qualified institutional buyer” within the meaning of Rule 144A under the Securities Act, and is acquiring the Shares fo…